Phillip Spark
University of Nottingham
4 Papers
80 Citations
Phillip Spark is an academic researcher from University of Nottingham. The author has contributed to research in topics: Carvedilol & Metoprolol. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial
Lars G. Olsson,Karl Swedberg,John G.F. Cleland,Phillip Spark,Michel Komajda,Marco Metra,Christian Torp-Pedersen,Willem J. Remme,Armin Scherhag,Philip A. Poole-Wilson,Comet investigators +10 more
TL;DR: Plasma levels of N‐terminal pro‐brain natriuretic peptide (NT‐pro BNP) are increased in patients with chronic heart failure and Beta‐blockers may influence these levels but it is unclear whether changes in NT‐ pro BNP reflect concomitant changes in prognosis.
82
Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure: Results From COMET
Willem J. Remme,Christian Torp-Pedersen,John G.F. Cleland,Philip A. Poole-Wilson,Marco Metra,Michel Komajda,Karl Swedberg,Andrea Di Lenarda,Phillip Spark,Armin Scherhag,Christine Moullet,Mary Ann Lukas +11 more
TL;DR: In this article, the authors explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprololine European Trial) study.
62
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
Willem J. Remme,John G.F. Cleland,Leif Rw Erhardt,Phillip Spark,Christian Torp-Pedersen,Marco Metra,Michel Komajda,Christine Moullet,Mary Ann Lukas,Philip A. Poole-Wilson,Andrea Di Lenarda,Karl Swedberg +11 more
TL;DR: In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II–IV heart failure and EF <35%, followed for an average of 58months.
41
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
Christian Torp-Pedersen,Marco Metra,Andrew Charlesworth,Phillip Spark,Mary Ann Lukas,Philip A. Poole-Wilson,Karl Swedberg,John G.F. Cleland,Andrea Di Lenarda,Willem J. Remme,Armin Scherhag +10 more
TL;DR: A high prevalence and incidence of diabetes is found in patients with heart failure over a course of 5 years, and new onset diabetes is more likely to occur during treatment with metoprolol than duringtreatment with carvedilol.